Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2011

View Archived Issues

Noninvasive method predicts organ rejection using donor DNA levels in transplant recipient's plasma

Lab-on-a-chip device SIMBAS enables quick separation of parasites from human blood

Antitumor effects of tolfenamic acid correlate with downregulation of transcription factors Sp1/3/4

Glenmark Pharma begins IND-enabling studies for GBR-401

Orexo advances development of OX-51 for pain

CPP-109 enters trial for cocaine and alcohol addiction

Astellas licenses three agents to Cardeus Pharma

America Stem Cell's ASC-101 obtains FDA orphan drug status

Novel microtubule-disrupting agents claimed

Enrollment begins in phase III EMPOWER trial of dexpramipexole in ALS

NeuroSearch patents new modulators of voltage-gated potassium channels

ISP Investments presents new protein-glutamine gamma-glutamyltransferase activator

Quest Diagnostics acquires Athena Diagnostics

Pfizer receives FDA refuse to file letter for tafamidis in TTR-FAP

Avanir Pharma files IND for AVP-923 for neuropathic pain in MS

Tibotec scientists design novel anti-HCV agents

New inhibitors of cyclin-dependent kinase 9 patented by Novartis

Pan-Akt inhibitor GDC-0068 demonstrates in vivo antitumor effects

Morphotek acquires tumor-targeting peptide platform from TransMolecular

Boston Scientific reports data on new alloy and stent design

Final SELECT-2 data show CR2b is efficacious against hepatitis C when dosed every 2 weeks

Daiichi Sanyko completes acquisition of Plexxikon

Reporting of final results of phase II AZX-100 trial to be delayed

Abstral launched in U.S. for breakthrough cancer pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...